Last reviewed · How we verify
NCT07304908
Effect of Perception-based Interventions on Public Acceptance of Using Large Language Models in Medicine
NA trial testing Perception-based interventions in Large Language Models in 3,000 participants. Participants enrolled and being followed up; not accepting new ones.
31 October 2026
Quick facts
| Lead sponsor | Peking University |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | other |
| Enrollment | 3,000 |
| Start date | 25 November 2025 |
| Primary completion | 31 October 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- Perception-based interventions
Conditions studied
- Large Language Models — all drugs for Large Language Models →
- Acceptability of Health Care — all drugs for Acceptability of Health Care →
- Perception, Self — all drugs for Perception, Self →
Sponsor
Peking University
Who can join
18 and older, any sex, with Large Language Models or Acceptability of Health Care. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Large language models (LLMs) show promise in medicine, but concerns about their accuracy, coherence, transparency, and ethics remain. To date, public perceptions on using LLMs in medicine and whether they play a role in the acceptability of health care applications of LLMs are not yet fully understood. This study aims to investigate public perceptions on using LLMs in medicine and if interventions for perceptions affect the acceptability of health care applications of LLMs.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07304908
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Large Language Models
Currently open trials in the same condition.
- NCT07367399 — Acute Myocardial Infarction Clinical Intelligent Decision Support System · active not recruiting
Other Peking University trials
Trials by the same sponsor.
- NCT07519122 — Fangshan Active Nutrition Initiative · NA · not yet recruiting
- NCT07466238 — HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer · NA · recruiting
- NCT07480525 — Efficacy and Mechanisms of Escitalopram in Drug-Naïve First-Episode Major Depressive Disorder · NA · not yet recruiting
- NCT07454031 — Intraperitoneal PX in Combination With Nab-Paclitaxel in Patients With Peritoneal Metastatic Mucinous Adenocarcinoma · Phase 1 · not yet recruiting
- NCT07466225 — HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07304908 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking University
- Last refreshed: 26 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07304908.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing